Regulatory Submission in Europe in Absence of Reference product [Regulatives / Guidelines]

posted by dshah  – India/United Kingdom, 2021-03-23 10:51 (1101 d 13:04 ago) – Posting: # 22290
Views: 6,822

Hi Abhay Patil!
In absence of Innovator product in EU and UK market for FDC, you may have to do BE against individual drug substance innovator product. Please see Guideline on clinical development of fixed combination medicinal products.
Regards,
Dshah

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
95 visitors (0 registered, 95 guests [including 10 identified bots]).
Forum time: 23:55 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5